Zydus Cadila gets USFDA approval for Misoprostol Tablets

USFDA has given the final approval to Zydus Cadila to market Misoprostol Tablets, 100 mcg and 200 mcg. The drug will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Misoprostol is used to prevent stomach ulcers in patients taking pain medications especially if the patient is at risk for developing ulcers or has a past history of ulcers. Misoprostol helps to decrease risk of serious ulcer complications such as bleeding.

The group now has 268 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

Last month, the company had completed enrolment of 104 patients with Non-Alcoholic Fatty Liver Disease (NAFLD), including Non-Alcoholic SteatoHepatitis (NASH) across 20 clinical sites in the United States of America.

Zydus Cadila, a leading Indian pharmaceutical company is a fully-integrated, global healthcare provider. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

On Wednesday, the stock of Cadila Healthcare opened at Rs. 236.90 per share. During the day, it made intra-day high and low of Rs. 238.65 and Rs. 232.30 per share, respectively.